Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease

WA Border, NA Noble, T Yamamoto, JR Harper… - Nature, 1992 - nature.com
WA Border, NA Noble, T Yamamoto, JR Harper, Y Yamaguchi, MD Pierschbacher…
Nature, 1992nature.com
THE central pathological feature of human kidney disease that leads to kidney failure is the
accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth
factor-β (TGF-β) underlies the accumulation of pathological matrix in experimental
glomerulonephritis1. Administration of an antibody raised against TGF-β to
glomerulonephritic rats suppresses glomerular matrix production and prevents matrix
accumulation in the injured glomeruli2. One of the matrix components induced by TGF-β, the …
Abstract
THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-β (TGF-β) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-β to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-β, the proteoglycan decorin, can bind TGF-β and neutralize its biological activity3, so decorin may be a natural regulator of TGF-β (refs 3,4). We tested whether decorin could antagonize the action of TGF-β in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-β.
nature.com